A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).

Francesco MenzellaMatteo FontanaCarla GaleoneMaria D'AmatoGiorgio Walter CanonicaGiulia GhidoniSilvia CapobelliChiara ScelfoAnna SimonazziChiara CatellaniPatrizia RuggieroNicola Facciolongo

Published in: Journal of asthma and allergy (2021)

To our knowledge, this is the first study to compare all marketed mAbs with BT, ending in more comprehensive and applicable results to clinical practice. All biologics, to varying degrees, reduced hospitalizations, exacerbations, and OCS use. The starting point for patients in the BT group was worse regarding hospitalizations, exacerbations and OCS, but despite this, even this non-pharmacological option obtained positive results, comparable to biologics.

Keyphrases

chronic obstructive pulmonary disease
end stage renal disease
clinical practice
cystic fibrosis
ejection fraction
chronic kidney disease
newly diagnosed
healthcare
lung function
prognostic factors
peritoneal dialysis
patient reported outcomes
allergic rhinitis
patient reported